Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents

NCT00088075 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00088075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Risperidone for the Treatment of Schizophrenia in Adolescents
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2004
Completion date
December 31, 2005
Enrollment
160 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia